Arterial stiffness indexes and serum cytokine levels in seronegative spondyloarthritis: relationships between stiffness markers and metabolic and immunoinflammatory variables

Objective: The aim of this study was to investigate the relationship between immunoinflammatory markers and indexes of arterial stiffness in patients with seronegative spondyloarthritis (SpA). Method: We enrolled consecutive patients with inflammatory seronegative SpA referred to a rheumatology outpatient clinic. Control subjects were patients admitted in the same period for any cause other than chronic inflammatory disease or acute cardiovascular and cerebrovascular events. Carotid-femoral pulse wave velocity (PWV) was measured and the aortic pressure waveform was used to calculate the augmentation index (Aix). We also evaluated plasma levels of C-reactive protein (CRP), interleukin (IL)-1β, tumour necrosis factor (TNF)-α, and interleukin (IL)-6 as markers of immunoinflammatory activation. Results: This study enrolled 53 patients with SpA and 55 control subjects. After adjustment for blood glucose, cholesterol, and triglyceride levels, and systolic (SBP) and diastolic blood pressure (DBP), patients with seronegative SpA showed higher mean PWV and Aix compared to controls. Moreover, in patients with seronegative SpA, we observed higher mean plasma levels of IL-6, IL-1β, and TNF-α in subjects with mean PWV > 8 m/s in comparison with those with PWV < 8 m/s. Multivariate analysis revealed a significant association between PWV > 8 m/s and male gender, age, diabetes, hypertension, low density lipoprotein cholesterol (LDL-C) > 120 mg/dL, total cholesterol (TC) > 200 mg/dL, coronary artery disease (CAD), microalbuminuria, carotid plaque, and plasma levels of IL-6, IL-1β, and TNF-α. Conclusions: These findings emphasize the role of inflammatory variables and metabolic factors in indexes of high arterial stiffness. Thus, an inflammatory-metabolic background may influence the pathogenesis of increased arterial stiffness in seronegative inflammatory arthritis.

[1]  T. Witte,et al.  Large vessel vasculitis and spondyloarthritis: coincidence or associated diseases? , 2014, Scandinavian journal of rheumatology.

[2]  宋鴻樟,et al.  A nationwide population-based retrospective cohort study: increased risk of acute coronary syndrome in patients with ankylosing spondylitis. , 2014 .

[3]  A. Tuttolomondo,et al.  Inflammation in ischemic stroke subtypes. , 2012, Current pharmaceutical design.

[4]  D. Atar,et al.  Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. , 2012, American journal of hypertension.

[5]  A. Tuttolomondo,et al.  Single nucleotide polymorphisms (SNPs) of pro-inflammatory/anti-inflammatory and thrombotic/fibrinolytic genes in patients with acute ischemic stroke in relation to TOAST subtype. , 2012, Cytokine.

[6]  A. Kırış,et al.  Anti-TNF-α therapy may not improve arterial stiffness in patients with AS: a 24-week follow-up. , 2012, Rheumatology.

[7]  P. Strazzullo,et al.  Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study , 2012, Clinical Rheumatology.

[8]  R. Kishi,et al.  Metabolic syndrome is a significant and independent risk factor for increased arterial stiffness in Japanese subjects , 2009, Hypertension Research.

[9]  A. Tuttolomondo,et al.  Plasma levels of inflammatory and thrombotic/fibrinolytic markers in acute ischemic strokes: Relationship with TOAST subtype, outcome and infarct site , 2009, Journal of Neuroimmunology.

[10]  J. Cohn,et al.  Relationship between C-reactive protein and arterial stiffness in an asymptomatic population , 2005, Journal of Human Hypertension.

[11]  D. Kass,et al.  Mechanisms, pathophysiology, and therapy of arterial stiffness. , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[12]  John Chalmers,et al.  World health organisation-international society of hypertension (WHO/ISH) hypertension guidelines. , 2004, Clinical and experimental hypertension.

[13]  D. Harrison,et al.  Vascular Oxidant Stress Enhances Progression and Angiogenesis of Experimental Atheroma , 2004, Circulation.

[14]  S. Anderson,et al.  Aortic Pulse-Wave Velocity and Its Relationship to Mortality in Diabetes and Glucose Intolerance: An Integrated Index of Vascular Function? , 2002, Circulation.

[15]  N. Düzgün,et al.  Serum levels of IL-1 beta, TNF-alpha, IL-8, and acute phase proteins in seronegative spondyloarthropathies. , 2002, Joint, bone, spine : revue du rhumatisme.

[16]  M. Kohno,et al.  Improvement of Aortic Wall Distensibility and Reduction of Oxidative Stress by Pioglitazone in Pre-diabetic Stage of Otsuka Long-Evans Tokushima Fatty Rats , 2002, Cardiovascular Drugs and Therapy.

[17]  M. Safar,et al.  Aortic Pulse Wave Velocity Predicts Cardiovascular Mortality in Subjects >70 Years of Age , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[18]  P. Ducimetiere,et al.  Aortic Stiffness Is an Independent Predictor of All-Cause and Cardiovascular Mortality in Hypertensive Patients , 2001, Hypertension.

[19]  G. Heiss,et al.  Hypertension and arterial stiffness: the Atherosclerosis Risk in Communities Study. ARIC Investigators. , 2000, American journal of hypertension.

[20]  R. Ross.  Atherosclerosis is an inflammatory disease , 1999 .

[21]  J. Blacher,et al.  Impact of aortic stiffness on survival in end-stage renal disease. , 1999, Circulation.

[22]  Y. Allanore,et al.  A relationship between TGF-beta 1 or IL-6 plasma levels and clinical features of spondyloarthropathies. , 1997, British journal of rheumatology.

[23]  R. Molina,et al.  SERUM CYTOKINES (IL-6, TNF-α, IL-1β AND IFN-γ) IN ANKYLOSING SPONDYLITIS: A CLOSE CORRELATION BETWEEN SERUM IL-6 AND DISEASE ACTIVITY AND SEVERITY , 1994 .

[24]  G. Davı̀,et al.  Double-blind multicenter trial on a new medium molecular weight glycosaminoglycan. Current therapeutic effects and perspectives for clinical use. , 1990, Atherosclerosis.

[25]  D. Bernard,et al.  Serum levels of interleukin 1-β, tumor necrosis factor-α, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies , 2004, Rheumatology International.

[26]  C. Allegra,et al.  Plasma levels of the molecular markers of coagulation and fibrinolysis in patients with peripheral arterial disease. , 1996, Seminars in thrombosis and hemostasis.

[27]  R. Molina,et al.  Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. , 1994, British journal of rheumatology.

[28]  D. Bernard,et al.  Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies. , 1994, Rheumatology international.